Xspray Pharma publishes Interim Report Q1, January-March 2019
May 16, 2019 ”Over the past year, we’ve tripled the number of employees and I’m very pleased to see that our entire team is performing high quality work with great commitment. Xspray is today a company well-equipped to take a drug all the way to a finished product.” Per Andersson, CEO Xspray Pharma AB (publ) […]
Read moreKerstin Hasselgren appointed CFO at Xspray Pharma
STOCKHOLM – May 3, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) today announces that Kerstin Hasselgren has been appointed CFO of the company. Kerstin has extensive experience from working in publicly listed international companies, including positions as Vice President Finance at AstraZeneca within Global R&D and Global Operations. Most recently, Kerstin comes from a position as […]
Read moreNotice of annual general meeting of Xspray Pharma AB (publ)
The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 23 May 2019 at 11.00 CEST at Advokatfirman Vinge’s office on Stureplan 8 in Stockholm. Registration starts at 10.30 CEST. Right to attend the annual general meeting Shareholders who wish to attend the annual general meeting […]
Read moreXspray Pharma announces positive clinical data for the drug candidate HyNap-Sora
STOCKHOLM – February 18, 2019. Xspray Pharma AB today announced the results of a clinical Phase I pilot study with its HyNap-Sora drug candidate. The study examined HyNap-Sora’s bioavailability compared to the sorafenib cancer drug, currently marketed as Nexavar® for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Both investigated HyNap compositions demonstrated […]
Read moreXspray Pharma publishes its Year-end Report, January – December 2018
”Following determined efforts, we demonstrated performance in 2018 that has brought us significantly closer to a market launch of HyNap-Dasa and have thus increased Xspray’s possibilities of building shareholder value.” Per Andersson, CEO Xspray Pharma AB (publ) Fourth quarter, October – December 2018, parent company Amounts in brackets refer to the corresponding period for the […]
Read moreXspray Pharma has carried out a directed share issue raising gross proceeds of approximately SEK 92 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release Solna, 6 December 2018 Xspray Pharma AB (publ) (“Xspray” or the […]
Read moreXspray Pharma contemplates a directed share issue to continue development of its product portfolio
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release Solna, 6 December 2018 Xspray Pharma AB (publ) (“Xspray” or the […]
Read moreAdditional product patent in the United States for HyNap-Dasa
STOCKHOLM, SWEDEN – December 4, 2018. Xspray Pharma AB (Nasdaq First North: XSPRAY) (“Xspray” or the “Company”) announces that the United States Patent and Trademark Office (USPTO) today has granted a new patent in the United States to Xspray. The new patent, US 10,143,683, covers the pharmaceutical composition of Xspray’s lead product candidate, HyNap-Dasa. This is Xspray’s third product […]
Read moreResolution on long-term incentive programme at extraordinary general meeting in Xspray Pharma on 28 November 2018
Xspray Pharma AB (publ) has today held an extraordinary general meeting where the meeting resolved, in accordance with the Board’s proposal, to adapt a long-term incentive programme (LTI 2018) and to issue a maximum of 234,505 warrants, entailing an increase of the share capital, at full exercise, of maximum SEK 234,505. LTI 2018 includes around 17 […]
Read moreXspray Pharma’s nomination committee for the annual general meeting 2019
STOCKHOLM, SWEDEN – November 23, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) publishes the nomination committee’s composition for the annual general meeting in 2019. The nomination committee, which has been appointed in accordance with the principles adopted by the annual general meeting on 14 May 2018, consists of: Gillis Cullin, appointed by Östersjöstiftelsen Anders Bladh, appointed by Ribbskottet […]
Read more